围产期HIV感染的药物预防

Pharmacologic prevention of perinatal HIV infection.

作者信息

Rakhmanina Natella Y, van den Anker Johannes N

机构信息

Division of Infectious Disease, Washington, DC, USA; Division of Pediatric Clinical Pharmacology, Children's National Health System, Washington, DC, USA; Elisabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA; Department of Pediatrics, the George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Division of Pediatric Clinical Pharmacology, Children's National Health System, Washington, DC, USA; Department of Pediatrics, the George Washington University School of Medicine and Health Sciences, Washington, DC, USA; Department of Pharmacology and Physiology, the George Washington University School of Medicine and Health Sciences, Washington, DC, USA; Intensive Care, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, the Netherlands; Department of Paediatric Pharmacology, University Children's Hospital Basel, Switzerland.

出版信息

Early Hum Dev. 2014 Mar;90 Suppl 1:S13-5. doi: 10.1016/S0378-3782(14)70005-2.

DOI:10.1016/S0378-3782(14)70005-2

PMID:24709447

Abstract

The goal of antiretroviral therapy for the prevention of mother-to-child transmission (PMTCT) of HIV is to achieve maximal suppression of maternal viral load with minimal maternal, fetal and infant toxicity during pregnancy, delivery and postpartum. In addition to the efficacy and toxicity of antiretroviral therapy, the consideration of HIV resistance in mothers and infected newborns further complicates therapeutic choices for PMTCT. This manuscript summarizes current approaches to PMTC in diverse international settings.

摘要

抗逆转录病毒疗法预防HIV母婴传播（PMTCT）的目标是在孕期、分娩期及产后最大程度抑制母体病毒载量，同时使母体、胎儿和婴儿的毒性降至最低。除了抗逆转录病毒疗法的疗效和毒性外，对母亲及受感染新生儿的HIV耐药性的考量进一步使PMTCT的治疗选择复杂化。本手稿总结了不同国际背景下PMTCT的当前方法。